Western Wealth Management LLC Acquires 349 Shares of Eli Lilly and Company $LLY

Western Wealth Management LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 4.2% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 8,664 shares of the company’s stock after buying an additional 349 shares during the period. Western Wealth Management LLC’s holdings in Eli Lilly and Company were worth $6,754,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Wealth Preservation Advisors LLC bought a new position in Eli Lilly and Company in the 1st quarter worth $27,000. Financial Gravity Companies Inc. purchased a new position in shares of Eli Lilly and Company during the second quarter valued at about $31,000. Blume Capital Management Inc. raised its stake in Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after buying an additional 14 shares in the last quarter. IMG Wealth Management Inc. purchased a new stake in Eli Lilly and Company in the second quarter worth about $35,000. Finally, TD Capital Management LLC lifted its holdings in Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after buying an additional 31 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,024.67 on Friday. The business has a fifty day moving average price of $826.89 and a 200-day moving average price of $780.14. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company has a market capitalization of $968.70 billion, a PE ratio of 66.97, a PEG ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,033.62.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on LLY. Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. UBS Group increased their price objective on Eli Lilly and Company from $895.00 to $1,080.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Loop Capital set a $950.00 target price on shares of Eli Lilly and Company in a report on Monday, November 10th. Finally, Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,015.11.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.